Sentia Medical Sciences Inc. Appoints Dr. Yvette Taché as Chair of the Scientific Advisory Board and Announces Award of a Phase 1 Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
Sentia Medical Sciences, Inc.
Jun. 12, 2018
SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Sentia announced today the appointment of Dr. Yvette Taché, Ph.D. as Chair of the Scientific Advisory Board. Dr. Taché, Ph.D. is a Distinguished Professor in the Vatche and Tamar Manoukian Digestive Diseases Division, David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Senior Research Career Scientist at the Veterans Affairs Medical Center, Los Angeles. Yvette is a world-renowned figure in the field of stress and gastrointestinal (GI) function and has received numerous recognitions for her work including the Middleton Award and Research Career Scientist Award from the Biomedical Laboratory Research and Development Department of Veterans Affairs, the Legion of Honor from the French government and the Outstanding Women in Science Award from the American Gastroenterology Association.
“We are delighted to have Yvette onboard as a key advisor to Sentia and we look forward to working together to bring novel therapies forward for patients,” said Dominic Behan, CEO of Sentia.
Sentia also announced today that it has been awarded a phase 1 small business innovation research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to support the development of astressins for the treatment of IBS. Astressins are potent and long-acting peptide antagonists of corticotropin releasing factor (CRF) receptors 1 and 2. CRF and urocortins are peptides that activate CRF1/2 receptors and are involved in the autonomic, behavioral, immune, reproductive and visceral responses to stress.
IBS is a functional bowel disorder of the GI tract that is characterized by recurrent abdominal pain and discomfort accompanied by alterations in bowel function, diarrhea, constipation, or a combination of both. Among the symptoms, abdominal pain is one of the most prevalent and significantly influences the quality of life of IBS patients, who represent 10-20% of the U.S. adult population. It is well established that stress plays a major role in the maintenance, and exacerbation of IBS symptoms.
About Sentia Medical Sciences Inc.
Sentia Medical Sciences Inc. is a privately held company with a vision to be the world leader in the development of novel peptide therapeutics to manage and cure stress-related diseases (www.sentiamedical.com).
Contact:Dominic Behan, Ph.D., D.Sc.Chief Executive OfficerSentia Medical Sciences Inc.3550 General Atomics CourtBuilding G02, Room 563San Diego, CA 92121858-886-7709 firstname.lastname@example.org